Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by abpagton May 14, 2013 5:10am
285 Views
Post# 21388335

rediculous P/CF ratio

rediculous P/CF ratio

message on kitco tells that a ration of 6,5 is average and is at lowest point and same point as 2008

for kitco this is message to tell time to buy

 

brigus

P/CF on operational cash flow

Based on calculation in last message:

CF for Q1= 24 milj :  with gold at 1425 (-4 milj)/cash costs at 680 (-1,3milj)/27000 ounces and  this will be forecasted  at 24-5,3=18,7 milj for Q2-3-4

makes operational cash flow for 2013 24+18,7+18,7 + 18,7=80 milj

so 80/330=0,24 per share so brigus trades at 0,66/0,24=2,6 times cash flow

 

forcasted at minimum 6,5 this gives= 6,5* 0,24=1,56 $

at midium 8 this gives = 8 * 0,14=1,9$

 

 

 

worst case senerio q2 will not be at 1200 so situation is really worst case !

cash flow Q1 24 Q2-Q3-Q4 at 1200$/680 cost and 27000

2013= 24 + 12,7 + 12,7 + 12,7= 60 milj

is 0,18 per share

at 6,5 multiple gives 1,18

at 8 gives 1,44

 

 

this stock is even at worst case rediculous !

who is keeping this down at all ratio's this is becoming one of the cheapest gold stocks on the planet

+

1) safe jurisdiction

2) joker: big production upgrade nearby 4 km (grey fox) with mine in place that can be upgraded with less capital than a new mine

 

Bullboard Posts